Company Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases.
The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL).
It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia.
It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies.
The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010.
IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Country | United States |
IPO Date | Sep 18, 2019 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 198 |
CEO | Mary Beth Harler M.D. |
Contact Details
Address: 325 East Middlefield Road Mountain View, California United States | |
Website | https://igmbio.com |
Stock Details
Ticker Symbol | IGMS |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001496323 |
CUSIP Number | 449585108 |
ISIN Number | US4495851085 |
Employer ID | 77-0349194 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Mary Beth Harler M.D. | Chief Executive Officer & Director |
Misbah Tahir CPA | Chief Financial Officer |
Dr. Angus M. Sinclair Ph.D. | Executive Vice President of Research |
Dr. Elizabeth Haanes J.D., Ph.D. | Senior Vice President of Intellectual Property |
Dr. Lisa L. Decker Ph.D. | Chief Business Officer |
Dr. Marvin S. Peterson Ph.D. | Executive Vice President of Process Development & Manufacturing |
Paul C. Graffagnino J.D. | Senior Vice President of Legal Affairs |
Steven Weber | Senior Vice President, Corporate Controller & Principal Accounting Officer |
Suzette Tauber | Chief Human Resources Officer |
TS Harigopal | Senior Vice President of Group Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 20, 2024 | 4 | Filing |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 12, 2024 | 4 | Filing |
Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 08, 2024 | 8-K | Current Report |
Nov 08, 2024 | 8-K/A | [Amend] Current Report |
Nov 08, 2024 | 10-Q | Quarterly Report |
Oct 04, 2024 | 4 | Filing |
Oct 03, 2024 | 8-K | Current Report |
Oct 02, 2024 | 4 | Filing |